m+Medelevator.RU
← Поиск публикаций
Cell communication and signaling : CCS · 2025

Targeting androgen receptor stability and degradation: approaches for developing a therapy for spinal and bulbar muscular atrophy.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cristofani Riccardo, Tedesco Barbara, Ferrari Veronica, Chierichetti Marta, Cozzi Marta, Pramaggiore Paola, Cornaggia Laura, Mohamed Ali, Casarotto Elena, Brodnanova Maria, Magdalena Rocio, Koshal Prashant, Piccolella Margherita, Crippa Valeria, Galbiati Mariarita, Poletti Angelo, Rusmini Paola

Аннотация

Conformational changes of proteins can occur due to mutations or stress conditions, altering their functionality through loss of physiological or gain of pathological function. A Protein Quality Control (PQC) system exists in cells to deal with the accumulation of misfolded proteins and aggregates, comprising a network of chaperones and degradative pathways to refold or remove the aberrant proteins. Protein misfolding and PQC system impairment lead to a broad range of diseases, including neurodegenerative and neuromuscular disorders, among them spinal and bulbar muscular atrophy (SBMA). SBMA is a neuromuscular disorder caused by a polyglutamine expansion (polyQ) in the androgen receptor (AR) protein. Expanded AR (ARexp) is highly prone to misfolding and aggregation, leading to its accumulation in affected tissues. Here, we summarise the dynamics that control AR protein stability and its degradation in physiological conditions. Next, we recapitulate the current knowledge of the molecular mechanisms of SBMA pathogenesis involving the PQC system. Finally, we provide an overview of promising approaches to SBMA intervention involving the modulation of PQC system functions to reduce ARexp accumulation and its toxic effects in affected cells.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты